Results for anden systemisk sygdom involverend... translation from Danish to English

kombination med anden systemisk anti-cancer-terapi
combination with other systemic anti-cancer therapies

må ikke bruges til dyr, hos hvem overvægt eller fedme skyldes samtidig systemisk sygdom som hypothyroidisme eller hyperfunktion af binyrebarken.
do not use in animals in which overweight or obesity is caused by a concomitant systemic disease such as hypothyroidism or hyperadrenocorticism.

bør ikke anvendes til hunde i de tilfælde, hvor overvægten eller fedmen skyldes en samtidig systemisk sygdom såsom hypothyroidisme eller hyperadrenocorticisme.
do not use in dogs in which overweight or obesity is caused by a concomitant systemic disease such as hypothyroidism or hyperadrenocorticism.

53% af disse patienter udviste enten manglende respons, var intolerante over for eller havde en kontraindikation mod anden systemisk behandling.
53% of these patients were either non-responsive, intolerant, or had a contraindication to other systemic therapy.

hos patienter i risiko- gruppe, der bliver behandlet med simponi, skal invasiv svampeinfektion mistænkes, hvis patienten udvikler en alvorlig systemisk sygdom.
in at-risk patients treated with simponi, an invasive fungal infection should be suspected if they develop a serious systemic illness.

levende svækkede vacciner (med undtagelse af gul feber, for hvilken samtidig brug er kontraindiceret): risiko for systemisk sygdom med mulig dødelig udgang.
live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): risk of systemic, possibly fatal, disease.

andre gul feber vaccine og andre levende, svækkede vacciner anbefales ikke, på grund af risikoen for systemisk sygdom, som kan være fatal, specielt hos patienter med immunosuppression.
others yellow fever and other live attenuated vaccines are not recommended due to the risk of systemic, possibly fatal, disease, particularly in immunosuppressed patients.

må ikke anvendes til hunde med alvorlig systemisk sygdom (klassificeret som asa iii-iv), f.eks. nyre- eller leversvigt i sidste fase.
do not use in dogs with severe systemic disease (graded as asa iii-iv) e.g. end stage renal or liver failure.

følgende samtidig brug frarådes: levende svækkede vacciner (med undtagelse af gul feber, for hvilken samtidig brug er kontraindiceret): risiko for systemisk sygdom med mulig dødelig udgang.
concomitant use not recommended: live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): risk of systemic, possibly fatal, disease.

humira er indiceret til behandling af moderat til svær kronisk plaque psoriasis hos voksne patienter, som ikke har responderet på, eller som har en kontraindikation mod, eller som er intolerante over for anden systemisk behandling herunder cyklosporin, methotrexat eller puva.
humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or puva.

hvis en eller flere aif'er, der forvaltes af en faif, potentielt kan udgøre en vigtig kilde til modpartsrisiko for et kreditinstitut eller en anden systemisk relevant institution i andre medlemsstater, bør sådanne oplysninger også udveksles med de relevante myndigheder.
if one or more aifs managed by an aifm could potentially constitute an important source of counterparty risk to a credit institution or other systemically relevant institutions in other member states, such information should also be shared with the relevant authorities.

udvalget besluttede derfor, at fordelene ved raptiva er større end risiciene til behandling af voksne patienter med moderat til svær kronisk plaque psoriasis, hos hvilke anden systemisk behandling, herunder ciclosporin, methotrexat og puva, enten ikke virker, er kontraindiceret eller ikke tåles.
therefore, the committee decided that raptiva’s benefits are greater than its risks for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contra-indication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and puva.

for patienter, som udvikler tegn og symptomer såsom feber, utilpashed, vægttab, svedeture, hoste, dyspnø, og/ eller pulmonale infiltrater eller anden alvorlig systemisk sygdom med eller uden samtidig shock, bør en invasiv fungicid infektion mistænkes, og administration af humira skal omgående afbrydes og passende antimykotisk behandling iværksættes.
for patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnea, and/ or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasivie fungal infection should be suspected and administration of humira should be promptly discontinued and appropriate antifungal therapy should be initiated.

75 plaque psoriasis behandling af voksne med moderat til svær plaque psoriasis, som har vist utilstrækkelig respons på, eller viste sig at være intolerante overfor, anden systemisk behandling inklusiv cyclosporin, methotrexat eller puva eller hvor den systemiske behandling inklusiv cyclosporin, methotrexat eller puva er kontraindiceret (se afsnit 5. 1).
treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or puva (see section 5.1).